Increasing evidence demonstrates that the aggressiveness, therapy-resistance, and disease-relapse exhibited by HER2+ breast cancer might be attributed to the presence of a small sub-population of cancer stem cells (CSCs) [6,7,8]. Here, ERBB2 is linked to breast carcinoma.